-
Re-thinking the perception of long-term opioid use in RMDs Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-09-18 Serge Perrot, Anne-Priscille Trouvin
Emerging data suggest that the frequency of long-term opioid use is high among individuals with rheumatic and musculoskeletal diseases, which is of concern given the risks of opioid misuse. But is long-term opioid use really that high or is the situation more complicated?
-
Placebo effects in osteoarthritis: implications for treatment and drug development Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-09-11 Tuhina Neogi, Luana Colloca
-
Metal–polyDNA nanoparticles reset the osteoporotic microenvironment Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-09-06 Robert Phillips
Nanoparticles consisting of long DNA molecules in association with Ca2+ and PPi4− ions can modulate the pathological osteoporotic microenvironment and promote bone repair.
-
Mechanisms and rationale for uricase use in patients with gout Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-09-08 Naomi Schlesinger, Fernando Pérez-Ruiz, Frédéric Lioté
-
Imaging in inflammatory arthritis: progress towards precision medicine Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-09-08 Ioanna Minopoulou, Arnd Kleyer, Melek Yalcin-Mutlu, Filippo Fagni, Stefan Kemenes, Christian Schmidkonz, Armin Atzinger, Milena Pachowsky, Klaus Engel, Lukas Folle, Frank Roemer, Maximilian Waldner, Maria-Antonietta D’Agostino, Georg Schett, David Simon
-
Innate immune memory in inflammatory arthritis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-09-06 Maxime M. Jeljeli, Iannis E. Adamopoulos
-
Properties of a new anti-IL-17 antibody Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-09-07 Robert Phillips
A monoclonal antibody targeting a peptide that replicates the proinflammatory properties of IL-17 has shown potent activity and an acceptable profile of adverse effects in pre-clinical studies.
-
HIF-1 inhibition mitigates skin damage in CLE Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-09-07 Jessica McHugh
HIF-1 can regulate the cytotoxic activity of skin-infiltrating T cells in cutaneous lupus erythematosus and is a potential therapeutic target.
-
CD38hiCD8+ T cells characterize ICI-mediated arthritis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-09-06 Robert Phillips
Although inflammatory arthritis induced by immune-checkpoint inhibitors clinically resembles that of rheumatoid arthritis or psoriatic arthritis, research shows that it differs in its associated T cell response.
-
PRESTO estimates PsA risk for patients with psoriasis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-09-06 Robert Phillips
A new tool, PRESTO, enables estimation of the 1-year and 5-year risks of the development of psoriatic arthritis in patients with psoriasis.
-
SGLT2 inhibitors protect podocytes in lupus nephritis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-09-04 Sarah Onuora
New research provides insights into the mechanisms underlying the renal protective effects of sodium glucose cotransporter 2 inhibitors in lupus nephritis.
-
Inflammation across tissues: can shared cell biology help design smarter trials? Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-09-04 Tom Hosack, Tom Thomas, Rahul Ravindran, Hans Holm Uhlig, Simon Piers Leigh Travis, Christopher Dominic Buckley
-
Repolarizing macrophages using antagomirs Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-09-07 Jessica McHugh
New findings suggest that liposome-mediated delivery of a specific microRNA inhibitor can restore anti-inflammatory macrophage polarization and reduce joint inflammation in mice.
-
Therapeutic potential in rheumatic diseases of extracellular vesicles derived from mesenchymal stromal cells Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-09-04 Giuliana Minani Bertolino, Marie Maumus, Christian Jorgensen, Danièle Noël
-
Fibroblast multiplicity in RA: a synovial state of affairs Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-08-21 Camilla R. L. Machado, Gary S. Firestein
-
Remote monitoring in rheumatology: seeing the right patient at the right time Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-08-07 Antoni Chan, Johannes Knitza
The rise in the use of digital health-care technologies such as electronic patient-reported outcome measures enables a transformation of the traditional care model. In light of the increasing demand for rheumatologists, telehealth could enable more efficient usage of scarce face-to-face appointments.
-
TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-08-04 Daniela Siegmund, Harald Wajant
-
Non-depleting anti-CD19 B cell inhibition Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-08-03 Robert Phillips
An antibody that targets CD19 on B cells has shown greater inhibitory efficacy than that of anti-CD20 B cell depletion therapy in animal models of autoimmune diseases.
-
Aminoacyl-tRNA synthetases function as alarmins in RA Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-08-03 Sarah Onuora
New research indicates that extracellular aminoacyl-tRNA synthetases contribute to the pathogenesis of rheumatoid arthritis by functioning as alarmins, and could be a novel therapeutic target.
-
Urchin-like nanoparticles for miRNA therapy of OA Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-08-03 Robert Phillips
Researchers have developed ‘urchin-like’ ceria nanoparticles with inherent antioxidant properties that efficiently carry therapeutic microRNA, enabling gene therapy following intra-articular injection in a mouse model of osteoarthritis.
-
Platelets promote cardiovascular complications in Kawasaki disease Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-08-02 Jessica McHugh
Platelet activity and the formation of monocyte–platelet aggregates contribute to the production of IL-1β and the development of cardiovascular lesions in Kawasaki disease.
-
Oral JAK inhibitor baricitinib effective in JIA Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-08-02 Jessica McHugh
In a phase III trial, the oral Janus kinase inhibitor baricitinib was safe and effective in patients with juvenile idiopathic arthritis who previously had an inadequate response to DMARD therapy.
-
Interosseous tendon inflammation associated with arthritis risk Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-08-02 Sarah Onuora
New findings suggest that interosseous tendon inflammation is already present in individuals with clinically suspect arthralgia and is linked to an increased risk of developing clinical arthritis.
-
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays? Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-07-31 Bruno Fautrel
Drug-free remission is a treatment goal in rheumatoid arthritis that can be achieved by tapering and discontinuation of biologic DMARDs. However, newly published real-world evidence suggests that DMARD discontinuation occurs less frequently than results of clinical trials suggest, so it is important to question what the ultimate goal of treatment should be.
-
Insights into juvenile myositis via engineered muscle Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-07-26 Hanna Kim
The pathogenesis of juvenile dermatomyositis (JDM) is complex and various evidence implicate a role for type I interferons. Could the use of a bioengineered paediatric skeletal muscle model provide insight into this disease and have potential for high throughput testing of therapeutic agents?
-
IL-17A and IL-17F in tissue homeostasis, inflammation and regeneration Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-07-24 Iannis E. Adamopoulos, Vijay Kuchroo
-
Heat of the night: sleep disturbance activates inflammatory mechanisms and induces pain in rheumatoid arthritis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-07-24 Michael R. Irwin, Rainer H. Straub, Michael T. Smith
-
A basket genetic trial of the vasculitides Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-07-12 Elena Carnero-Montoro, Marta E. Alarcón-Riquelme
-
Effect of DMARDs on the immunogenicity of vaccines Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-07-12 Yannick van Sleen, Kornelis S. M. van der Geest, Anke L. W. Huckriede, Debbie van Baarle, Elisabeth Brouwer
-
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-07-11 Kathryn Connelly, Laura E. Eades, Rachel Koelmeyer, Darshini Ayton, Vera Golder, Rangi Kandane-Rathnayake, Kate Gregory, Hermine Brunner, Laurie Burke, Laurent Arnaud, Anca Askanase, Cynthia Aranow, Ed Vital, Guillermo Pons-Estel, Khadija Dantata, Jeanette Andersen, Alain Cornet, Joy Buie, Ying Sun, Yoshiya Tanaka, Lee Simon, Youmna Lahoud, Alan Friedman, Kenneth Kalunian, Qing Zuraw, Victoria Werth
-
Low back pain is a growing concern Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-07-10 Sarah Onuora
A new report indicates that low back pain remains the leading cause of disability worldwide, and that case numbers are expected to increase substantially in the coming decades.
-
New T cell target of methotrexate identified Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-07-10 Jessica McHugh
New findings implicate TAp63 as a potential target of methotrexate in T cells, providing insight in the mechanism of action of this drug, including its suppressive effects on regulatory T cells.
-
NETs implicated in periodontitis-associated bone loss Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-07-10 Sarah Onuora
New findings suggest that neutrophil extracellular traps and their components have a functional role as triggers of IL-17-mediated inflammation and associated bone destruction in periodontitis.
-
The bone marrow side of axial spondyloarthritis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-07-05 Daniele Mauro, Saviana Gandolfo, Enrico Tirri, Georg Schett, Walter P. Maksymowych, Francesco Ciccia
-
Progress toward ‘bone-on-a-chip’ Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-07-04 Robert Phillips
Researchers have co-cultured human mesenchymal stromal cells and monocytes to generate bone-like structures that have the potential to facilitate the study of bone remodelling in vitro.
-
New guideline for integrative approaches to RA management Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-07-03 Jessica McHugh
The ACR has developed its first guideline for managing rheumatoid arthritis using integrative interventions, to aid in decision-making regarding such approaches alongside pharmacological treatment.
-
Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-06-29 Giacomo Cozzi, Laura Scagnellato, Mariagrazia Lorenzin, Edoardo Savarino, Fabiana Zingone, Francesca Ometto, Marta Favero, Andrea Doria, Stephan R. Vavricka, Roberta Ramonda
-
Response to inflammation differs in gut and joint Treg cells Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-06-27 Robert Phillips
New research demonstrates that regulatory T cells in gut and joint tissues differ in their response to and ability to control TNF-mediated inflammation.
-
Complement therapeutics are coming of age in rheumatology Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-06-19 V. Michael Holers
-
A leading role for interferon as a treatment target in Sjögren syndrome Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-06-15 Gwenny M. Verstappen, Frans G. M. Kroese
-
Post-transcriptional checkpoints in autoimmunity Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-06-13 Rami Bechara, Stephan Vagner, Xavier Mariette
-
Disease stratification in GCA and PMR: state of the art and future perspectives Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-06-12 Alessandro Tomelleri, Kornelis S. M. van der Geest, Muhammad Asim Khurshid, Alwin Sebastian, Fiona Coath, Daniel Robbins, Barbara Pierscionek, Christian Dejaco, Eric Matteson, Yannick van Sleen, Bhaskar Dasgupta
-
Failure of cartilage regeneration: emerging hypotheses and related therapeutic strategies Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-06-09 Sathish Muthu, Jasmijn V. Korpershoek, Emanuel J. Novais, Gwenllian F. Tawy, Anthony P. Hollander, Ivan Martin
-
Cognitive functional therapy improves low back pain Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-06-07 Jessica McHugh
Cognitive functional therapy is a safe, effective and low-cost intervention for individuals with persistent disabling low back pain, according to results from the phase III RESTORE trial.
-
Rheumatic diseases on the rise Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-06-07 Sarah Onuora
Results of a population-based cohort study of more than 20 million individuals in the UK reveal that the incidence of several autoimmune disorders, and of rheumatic diseases in particular, continues to increase over time.
-
Notch signalling mediates OA pain in mice Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-06-07 Jessica McHugh
Notch signalling in the peripheral nervous system is involved in mediating pain in a mouse model of osteoarthritis.
-
Bone-forming properties of an ascorbic acid derivative Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-06-06 Robert Phillips
Magnesium ascorbyl phosphate is a stable derivative of ascorbic acid that has now been shown to promote bone formation via stimulation of the CAMKIIα pathway.
-
Reprogramming autologous cells to treat OA Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-05-31 Robert Phillips
A new treatment for osteoarthritis that combines cells from the patient in vitro prior to intra-articular injection has demonstrated beneficial effects on arthritic joints in a compassionate use study.
-
Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-05-25 Brittany N. Weber, Jon T. Giles, Katherine P. Liao
-
Bone marrow lesions: plugging the holes in our knowledge using animal models Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-05-24 Rebecca T. Hansen, Chantal Chenu, Nidhi Sofat, Andrew A. Pitsillides
-
PJP prophylaxis with rituximab Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-05-22 Sarah Onuora
In a retrospective study, risk–benefit analyses suggest that primary prophylaxis against Pneumocystis jirovecii pneumonia is beneficial in patients receiving rituximab and high-dose glucocorticoids.
-
Which DMARD for ICI-associated arthritis? Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-05-22 Sarah Onuora
In a retrospective study, biologic DMARD therapy was associated with faster control of immune checkpoint inhibitor-associated arthritis but also with a shorter time to cancer progression, compared with methotrexate therapy.
-
Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-05-15 Charalampia Papadopoulou, Christine Chew, Meredyth G. Ll. Wilkinson, Liza McCann, Lucy R. Wedderburn
-
Targeting KDM2/7 histone demethylases could protect against OA Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-05-10 Sarah Onuora
New research suggests that pharmacological restoration of H3K79 methylation could offer a way to prevent osteoarthritis onset and progression.
-
Antibodies cross-reactive with DNase1L3 and dsDNA discovered Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-05-10 Sarah Onuora
Clinical and molecular analysis of autoantibodies against the endonuclease DNase1L3 in patients with systemic lupus erythematosus led to the identification of a subset of pathogenetic antibodies that are cross-reactive with double-stranded DNA.
-
Gut metabolite mediates neoantigen generation in AS Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-05-09 Jessica McHugh
In screening for post-translational modifications associated with ankylosing spondylitis, researchers have identified a microbiome-metabolite-mediated modification that can lead to neoantigen generation and subsequent autoimmunity.
-
G-CSF implicated as therapeutic target in APLAID Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-05-09 Jessica McHugh
Characterization of a new mouse model highlights allogeneic bone marrow transplantation and granulocyte colony-stimulating factor neutralization as potential avenues for the treatment of APLAID.
-
Matrix metalloproteinases in arthritis: towards precision medicine Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-05-09 Bernard Grillet, Rafaela Vaz Sousa Pereira, Jo Van Damme, Ahmed Abu El-Asrar, Paul Proost, Ghislain Opdenakker
-
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-05-09 Giacomo Emmi, Alessandra Bettiol, Elena Gelain, Ingeborg M. Bajema, Alvise Berti, Stella Burns, Maria C. Cid, Jan W. Cohen Tervaert, Vincent Cottin, Eugenia Durante, Julia U. Holle, Alfred D. Mahr, Marcos Martinez Del Pero, Chiara Marvisi, John Mills, Sergey Moiseev, Frank Moosig, Chetan Mukhtyar, Thomas Neumann, Iacopo Olivotto, Carlo Salvarani, Benjamin Seeliger, Renato A. Sinico, Camille Taillé
-
A safe and effective treatment for MAS Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-05-05 Robert Phillips
Phase II trial results demonstrate rapid remission of macrophage activation syndrome in patients treated with the anti-IFNγ antibody emapalumab.